The anti-inflammatory drug Dupixent (dupilumab) has generated positive data in a pivotal trial of patients with eosinophilic esophagitis, a chronic, allergic inflammatory disease of the esophagus. Part A of the Phase 3 trial, which enrolled patients 12 years and older, demonstrated significant clinical and anatomic improvements, including the ability to swallow, the developers Sanofi SA and Regeneron Pharmaceuticals Inc announced on 23 May.

Roche has expanded its diagnostic capabilities with the acquisition of Seattle, US-based Stratos Genomics Inc, an early-stage sequencing technology company. The deal was announced on 22 May but financial details were not disclosed.